Cambridge, MA, December 27, 2005 � Therion Biologics Corporation has secured a $50 million line of credit from its investors, providing funding for the Company�s operations into 2007. The financing was provided by investor/philanthropist Hans-Werner Hector, one of the founders of the world�s leading enterprise software company, SAP AG.

�Therion is on track to accomplish two major milestones in 2005 with the completion of patient enrollment in its Phase II prostate cancer trial and the expectation to finalize accrual in its pivotal Phase III pancreatic cancer trial,� stated Mr.Hector. �The financing will allow Therion to prepare for a BLA filing of PANVAC-VF in 2006 and continue its preparation for commercialization.�

Therion will use the funds for the clinical advancement of its two targeted cancer therapeutics PANVAC-VF and PROSTVAC�-VF, to treat pancreatic cancer and prostate cancer, respectively. In late 2003, the Company initiated a Phase II trial of PROSTVAC-VF in prostate cancer and initiated in mid-2004 a pivotal Phase III trial of PANVAC-VF in advanced pancreatic cancer under a Special Protocol Assessment with the FDA. Clinical data from both trials are expected in the first half of 2006.

�The continued support from our investors reflects our track record of consistently meeting our scientific and operational milestones,� said Mark Leuchtenberger, President and Chief Executive Officer of Therion Biologics Corporation. �2006 will be an exciting year for our investors, our employees, and the patients as we�re planning for a BLA filing and possible product launch of PANVAC-VF.�


About Therion Biologics Corporation
Therion Biologics Corporation is a leader in the development of novel targeted cancer therapeutics designed to selectively seek out and destroy malignant cells without the serious side effects associated with cytotoxic chemotherapy. The Company has two lead product candidates:
� PANVAC-VF is in a Phase III registration trial for the treatment of pancreatic cancer;
� PROSTVAC�-VF is in Phase II trials for the treatment of prostate cancer.

In addition to these lead product candidates, clinical trials evaluating Therion�s innovative targeted therapeutics in colorectal, ovarian, breast and lung cancers are also ongoing or planned. Therion�s strategic partners are the National Cancer Institute (NCI) and a network of renowned clinical institutions.

Therion�s technology platform has been evaluated over a 13-year period in more than 30 clinical trials comprising close to 1000 patients, chiefly through the Company�s longstanding partnership with the NCI. This extensive research has enabled Therion to clinically optimize its technology and maximize the probability for downstream success. Therion�s two lead product candidates, PANVAC-VF and PROSTVAC-VF, are a direct result of these efforts.

For more information, please visit www.therion.com

Contacts:
Titus M.F.M. Plattel
Senior Director, Marketing
Therion Biologics Corporation
(617) 475.7312
[email protected]

Kari Watson
MacDougall Biomedical Communications
(508) 647.0209
[email protected]